FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024848314> ?p ?o ?g. }

• W3024848314 endingPage "167" @default.
• W3024848314 startingPage "167" @default.
• W3024848314 abstract "Background and objectives The aim of this observational retrospective cohort study was to demonstrate indications and response rates of the patients with pediatric rheumatic diseases that used canakinumab. Method The files of the patients that used canakinumab between December 2012 and July 2017 were reviewed. Canakinumab was used in 29 patients. Diagnosis of the patients were; colchicine resistant familial Mediterranean fever (crFMF) (19 cases), hyperimmunoglobulin D syndrome-mevalonate kinase deficiency (HIDS-MKD) (3 cases), cryopyrin-associated periodic syndrome (3 cases), systemic juvenile idiopathic arthritis (sJIA) (2 cases), idiopathic recurrent pericarditis (1 case) and pyoderma gangrenosum (1 case). Results Canakinumab was used for 21.8 ± 15.8 months (6-54 months). crFMF patients had a female predominance; 16 girls and 3 boys. Mean age at the first symptoms of FMF was 2.8 ± 2.2 years. Mean number of attacks per year before colchicine was 18.7 ± 6.9 (10-36), after colchicine was 8.2 ± 2.7 (6-12) and after biologic agent the number dropped to 0.1 ± 0.3 (0-1). Canakinumab led to resolution of attacks in 3 HIDS-MKD cases. Two familial cold autoinflammatory syndrome patients were using canakinumab for 13 months with total remission. Chronic infantile neurological cutaneous articular syndrome patient did not show dramatic response to standard doses of IL-1 blockers and remission was achieved with high doses of canakinumab. Canakinumab led to the resolution of all systemic and articular manifestations in one sJIA case but the other sJIA case developed polyarticular joint involvement under canakinumab treatment. A severe pyoderma gangrenosum patient that failed dapson and anakinra, also failed canakinumab treatment that was used for 9 months. We have successfully treated a case of idiopathic recurrent pericarditis with canakinumab. Canakinumab was discontinued due to inefficacy only in two cases. Conclusion Overall efficacy of canakinumab was 93.1% in this study. No major adverse event was observed under canakinumab treatment. Canakinumab seems to be effective and safe in children with rheumatic diseases." @default.
• W3024848314 created "2020-05-21" @default.
• W3024848314 creator A5024754731 @default.
• W3024848314 creator A5033632679 @default.
• W3024848314 creator A5083981582 @default.
• W3024848314 date "2020-01-01" @default.
• W3024848314 modified "2023-10-16" @default.
• W3024848314 title "Canakinumab in colchicine resistant familial mediterranean fever and other pediatric rheumatic diseases" @default.
• W3024848314 doi "https://doi.org/10.24953/turkjped.2020.02.001" @default.
• W3024848314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32419407" @default.
• W3024848314 hasPublicationYear "2020" @default.
• W3024848314 type Work @default.
• W3024848314 sameAs 3024848314 @default.
• W3024848314 citedByCount "8" @default.
• W3024848314 countsByYear W30248483142021 @default.
• W3024848314 countsByYear W30248483142022 @default.
• W3024848314 countsByYear W30248483142023 @default.
• W3024848314 crossrefType "journal-article" @default.
• W3024848314 hasAuthorship W3024848314A5024754731 @default.
• W3024848314 hasAuthorship W3024848314A5033632679 @default.
• W3024848314 hasAuthorship W3024848314A5083981582 @default.
• W3024848314 hasBestOaLocation W30248483141 @default.
• W3024848314 hasConcept C126322002 @default.
• W3024848314 hasConcept C16005928 @default.
• W3024848314 hasConcept C2776636253 @default.
• W3024848314 hasConcept C2779134260 @default.
• W3024848314 hasConcept C2779537928 @default.
• W3024848314 hasConcept C2779725882 @default.
• W3024848314 hasConcept C2781228260 @default.
• W3024848314 hasConcept C71924100 @default.
• W3024848314 hasConceptScore W3024848314C126322002 @default.
• W3024848314 hasConceptScore W3024848314C16005928 @default.
• W3024848314 hasConceptScore W3024848314C2776636253 @default.
• W3024848314 hasConceptScore W3024848314C2779134260 @default.
• W3024848314 hasConceptScore W3024848314C2779537928 @default.
• W3024848314 hasConceptScore W3024848314C2779725882 @default.
• W3024848314 hasConceptScore W3024848314C2781228260 @default.
• W3024848314 hasConceptScore W3024848314C71924100 @default.
• W3024848314 hasIssue "2" @default.
• W3024848314 hasLocation W30248483141 @default.
• W3024848314 hasOpenAccess W3024848314 @default.
• W3024848314 hasPrimaryLocation W30248483141 @default.
• W3024848314 hasRelatedWork W1765607015 @default.
• W3024848314 hasRelatedWork W1991378232 @default.
• W3024848314 hasRelatedWork W2464113330 @default.
• W3024848314 hasRelatedWork W2511004419 @default.
• W3024848314 hasRelatedWork W2523397474 @default.
• W3024848314 hasRelatedWork W2787958279 @default.
• W3024848314 hasRelatedWork W2883835606 @default.
• W3024848314 hasRelatedWork W2999186300 @default.
• W3024848314 hasRelatedWork W2999594830 @default.
• W3024848314 hasRelatedWork W3010460307 @default.
• W3024848314 hasVolume "62" @default.
• W3024848314 isParatext "false" @default.
• W3024848314 isRetracted "false" @default.
• W3024848314 magId "3024848314" @default.
• W3024848314 workType "article" @default.